FDA Feedback 'Best Case Scenario' for Sarepta Therapeutic (SRPT), Baird Said; PT Lifted
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) and boosted his price target from $35 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE